Pfizer's diverse operations put it in an excellent position to grow in the long run. It doesn't have a top weight loss treatment on the market, but that could change. Its above-average dividend yield ...

The following content has been reviewed by a licensed attorney. Depo-Provera, a widely used injectable contraceptive, has ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

The pharmaceutical giant's stock has severely lagged the broader market in 2024, falling 2.43% while the S&P 500 has surged ...

Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower ...

Pfizer’s revenue from pharmaceuticals declined Pharmaceutical giant Pfizer is getting into the health care delivery business.

Pfizer Inc. failed to warn patients that its injectable contraceptive drug Depo-Provera can increase the risk of developing ...

Pfizer now expects between $61 billion and $64 billion in revenue for the year and raised its outlook for adjusted earnings ...

Pfizer reported an adjusted EPS of $1.06, exceeding estimates by over 72%. Revenue reached $17.7 billion, marking a 32% year ...

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

It is a critical quarterly report for Pfizer, which is grappling with a proxy battle waged by the activist investor Starboard Value.